Tags

Type your tag names separated by a space and hit enter

Supplementation of n-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: A Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea.
Ann Nutr Metab. 2015; 66(2-3):141-148.AN

Abstract

BACKGROUND

Controversy over the efficacy of n-3 polyunsaturated fatty acids (PUFAs) in depression continues to this day. The present study investigated the hypothesis that n-3 PUFA supplementation reduces depressive symptoms in Korean patients with major depressive disorder.

METHODS

In a randomized, double-blind, placebo-controlled, 12-week, parallel-group trial, 35 patients with Center for Epidemiological Studies Depression Scale Korean version (CES-D-K) scores ≥25 and depression confirmed by a psychiatrist were assigned to take either 3 capsules of n-3 PUFAs (1,140 mg of EPA + 600 mg of DHA; n = 18) or placebo (olive oil + safflower oil; n = 17).

RESULTS

Supplementation with n-3 PUFAs significantly reduced Clinical Global Impression Improvement (CGI-I) scores as compared with intake of placebo using intention-to-treat analysis with last-observation-carried-forward after adjusting for energy, fat, and fish intake. However, the CES-D-K, Hamilton Depression Rating Scale-17, and Clinical Global Impression Scale scores did not significantly differ between the n-3 PUFA and placebo groups. After supplementation with n-3 PUFAs, the erythrocyte levels of n-3 PUFAs were significantly increased, but n-6 PUFA levels were decreased.

CONCLUSIONS

n-3 PUFAs demonstrated an advantage over placebo that did not reach clinical significance, although CGI-I score was significantly decreased in the n-3 PUFA group as compared with the placebo group.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25824637

Citation

Park, Yongsoon, et al. "Supplementation of N-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: a Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea." Annals of Nutrition & Metabolism, vol. 66, no. 2-3, 2015, pp. 141-148.
Park Y, Park YS, Kim SH, et al. Supplementation of n-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: A Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea. Ann Nutr Metab. 2015;66(2-3):141-148.
Park, Y., Park, Y. S., Kim, S. H., Oh, D. H., & Park, Y. C. (2015). Supplementation of n-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: A Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea. Annals of Nutrition & Metabolism, 66(2-3), 141-148. https://doi.org/10.1159/000377640
Park Y, et al. Supplementation of N-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: a Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea. Ann Nutr Metab. 2015;66(2-3):141-148. PubMed PMID: 25824637.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Supplementation of n-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: A Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea. AU - Park,Yongsoon, AU - Park,Yoo-Sin, AU - Kim,Seok Hyeon, AU - Oh,Dong Hoon, AU - Park,Yong-Chon, Y1 - 2015/03/24/ PY - 2014/11/12/received PY - 2015/01/30/accepted PY - 2015/4/1/entrez PY - 2015/4/1/pubmed PY - 2016/1/21/medline SP - 141 EP - 148 JF - Annals of nutrition & metabolism JO - Ann Nutr Metab VL - 66 IS - 2-3 N2 - BACKGROUND: Controversy over the efficacy of n-3 polyunsaturated fatty acids (PUFAs) in depression continues to this day. The present study investigated the hypothesis that n-3 PUFA supplementation reduces depressive symptoms in Korean patients with major depressive disorder. METHODS: In a randomized, double-blind, placebo-controlled, 12-week, parallel-group trial, 35 patients with Center for Epidemiological Studies Depression Scale Korean version (CES-D-K) scores ≥25 and depression confirmed by a psychiatrist were assigned to take either 3 capsules of n-3 PUFAs (1,140 mg of EPA + 600 mg of DHA; n = 18) or placebo (olive oil + safflower oil; n = 17). RESULTS: Supplementation with n-3 PUFAs significantly reduced Clinical Global Impression Improvement (CGI-I) scores as compared with intake of placebo using intention-to-treat analysis with last-observation-carried-forward after adjusting for energy, fat, and fish intake. However, the CES-D-K, Hamilton Depression Rating Scale-17, and Clinical Global Impression Scale scores did not significantly differ between the n-3 PUFA and placebo groups. After supplementation with n-3 PUFAs, the erythrocyte levels of n-3 PUFAs were significantly increased, but n-6 PUFA levels were decreased. CONCLUSIONS: n-3 PUFAs demonstrated an advantage over placebo that did not reach clinical significance, although CGI-I score was significantly decreased in the n-3 PUFA group as compared with the placebo group. SN - 1421-9697 UR - https://www.unboundmedicine.com/medline/citation/25824637/Supplementation_of_n_3_Polyunsaturated_Fatty_Acids_for_Major_Depressive_Disorder:_A_Randomized_Double_Blind_12_Week_Placebo_Controlled_Trial_in_Korea_ L2 - https://www.karger.com?DOI=10.1159/000377640 DB - PRIME DP - Unbound Medicine ER -